The effectiveness of the triple combination of dabrafenib, trametinib and pembrolizumab has been investigated in the phase I/II KEYNOTE-022 trial (NCT02130466) that enrolled previously untreated BRAF-mutated advanced melanoma patients. This evidence concerns the gene BRAF and melanoma.